Last reviewed · How we verify
Active Comparator: Olaparib tablets
Olaparib inhibits poly(ADP-ribose) polymerase (PARP) enzymes, preventing DNA repair in cancer cells and causing cell death, particularly in BRCA-mutant tumors.
Olaparib inhibits poly(ADP-ribose) polymerase (PARP) enzymes, preventing DNA repair in cancer cells and causing cell death, particularly in BRCA-mutant tumors. Used for BRCA-mutant metastatic breast cancer, BRCA-mutant ovarian cancer, BRCA-mutant pancreatic cancer.
At a glance
| Generic name | Active Comparator: Olaparib tablets |
|---|---|
| Also known as | Olaparib tablets |
| Sponsor | AstraZeneca |
| Drug class | PARP inhibitor |
| Target | PARP1, PARP2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
PARP inhibitors block the repair of single-strand DNA breaks. In cells with BRCA1/2 mutations (deficient in homologous recombination repair), this leads to accumulation of DNA damage and synthetic lethality. Olaparib is effective in cancers with homologous recombination deficiency, including BRCA-mutant and other HRD-positive tumors.
Approved indications
- BRCA-mutant metastatic breast cancer
- BRCA-mutant ovarian cancer
- BRCA-mutant pancreatic cancer
- Homologous recombination deficiency-positive ovarian cancer (maintenance therapy)
- Castration-resistant prostate cancer with HRD
Common side effects
- Anemia
- Nausea
- Fatigue
- Vomiting
- Diarrhea
- Thrombocytopenia
- Leukopenia
- Headache
Key clinical trials
- Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer (PHASE2)
- A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (PHASE3)
- A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Active Comparator: Olaparib tablets CI brief — competitive landscape report
- Active Comparator: Olaparib tablets updates RSS · CI watch RSS
- AstraZeneca portfolio CI